- Statistically significant treatment difference of -14.0 cm³ in total HO lesion volume favoring zilurgisertib (p=0.003)
- Zero patients developed new HO lesions on zilurgisertib vs. 1 patient (7.7%) on control
- Clinician-assessed joint mobility (CAJIS) improved by -0.80 points vs. -0.09 points
?? Positive AI Sentiment (+6.5 / 10)